Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Frexalimab - ImmuNext/Sanofi

Next Previous
Drug Profile

Frexalimab - ImmuNext/Sanofi

Alternative Names: INX 021; SAR-441344

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuNext
  • Developer Sanofi
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Discontinued Sjogren's syndrome

Most Recent Events

  • 27 Feb 2025 Pharmacodynamics and adverse events data from a preclinical trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)
  • 27 Feb 2025 Pharmacodynamics data from a preclinical trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS-2025)
  • 18 Sep 2024 Updated efficacy data from a phase II OLE trial in Multiple sclerosis presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top